Evidence map›Paper›PMID 40111510›Full record

Observational studyLung2025

Plasma Reticulocalbin 3 (RCN3) is a Novel Biomarker for the Early Diagnosis of Hepatopulmonary Syndrome in Cirrhotic Patients.

Fangping Ding, Liu Yang, Wenhui Cao, Jie Sun, Fengwei Shi, Yingfei Wang, Caixia Hu, Weiwei Kang, Jing Han, Qingkun Song and 2 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fangping Ding *Department of Respiratory and Critical Care Medicine, Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, No.8 Xi Tou Tiao, Youanmen Wai, Beijing, China.
Liu Yang *Department of Respiratory and Critical Care Medicine, Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, No.8 Xi Tou Tiao, Youanmen Wai, Beijing, China.
Wenhui Cao *Department of Respiratory and Critical Care Medicine, Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, No.8 Xi Tou Tiao, Youanmen Wai, Beijing, China.
Jie SunDepartment of Respiratory and Critical Care Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Fengwei ShiDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, No.8 Xi Tou Tiao, Youanmen Wai, Beijing, China.
Yingfei WangDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, No.8 Xi Tou Tiao, Youanmen Wai, Beijing, China.
Caixia HuHepatic Disease and Tumor Interventional Treatment Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Weiwei KangFourth Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Jing HanUltrasound and Functional Diagnosis Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Qingkun SongDepartment of Clinical Epidemiology, Department of Center of Biobank, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Yingmin MaDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, No.8 Xi Tou Tiao, Youanmen Wai, Beijing, China. mayingmin@ccmu.edu.cn.
Jiawei JinDepartment of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, N0.5 Jingyuan Road, Beijing, China. jiaweijin@ccmu.edu.cn.

Funding

Beijing Natural Science Foundation grant 7252053
6 · The paper itself

Abstract

backgroundHepatopulmonary syndrome (HPS) is a severe complication in cirrhotic patients and characterized by abnormal intrapulmonary vasodilation (IPVD), resulting in impaired oxygenation. Recent studies highlight the pivotal role and clinical merit of Reticulocalbin 3 (RCN3) in interstitial pulmonary remodeling.

objectivesThis study aimed to investigate the clinical value of plasma RCN3 for early diagnosis of HPS in cirrhotic patients.

methodsThis prospective observational study on a cohort including 41 healthy control subjects and 247 cirrhotic patients with/without HPS, in which most HPS occurs in the mild stage. Plasma levels of RCN3 and key HPS-associated vasoactive factors are compared between patients with and without HPS/IPVD. The predictive value of RCN3 for the diagnosis of HPS is further analyzed.

resultsPatients with HPS had a severe condition. Plasma RCN3 was decreased in cirrhotic patients versus health control, but it is significantly higher in patients with HPS/IPVD than without non-HPS/IPVD. Notably, RCN3 level is positively correlated with P(A-a)O

conclusionsCirculating RCN3 is likely a relatively specific earlier biomarker for the prediction of early or latent HPS in cirrhotic patients, and the combination of RCN3-ALB can achieve more efficiency in HPS prediction.

Indexed as

Calcium-Binding ProteinsHepatopulmonary SyndromeLiver CirrhosisAdultAgedBiomarkersCase-Control StudiesEarly DiagnosisFemaleHumansMaleMiddle AgedPredictive Value of TestsProspective StudiesROC CurveSeverity of Illness IndexBiomarkersCalcium-Binding ProteinsVascular Endothelial Growth Factor AAlbumin (ALB)CirrhosisHepatopulmonary syndrome (HPS)Intrapulmonary vascular dilatations (IPVD)Portal hypertensionReticulocalbin 3 (RCN3)

Identifiers

PMID40111510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.